These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 20683)

  • 1. Treatment of detrusor hyperreflexia in multiple sclerosis: a double-blind, crossover clinical trial comparing methantheline bromide (Banthine), flavoxate chloride (Urispas) and meladrazine tartrate (Lisidonil).
    Hebjorn S
    Urol Int; 1977; 32(2-3):209-17. PubMed ID: 20683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An objective comparison of the effects of parenterally administered drugs in patients suffering from detrusor instability.
    Cardozo LD; Stanton SL
    J Urol; 1979 Jul; 122(1):58-9. PubMed ID: 458990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emepronium bromide and flavoxate hydrochloride in the treatment of urinary incontinence associated with detrusor instability in elderly women.
    Robinson JM; Brocklehurst JC
    Br J Urol; 1983 Aug; 55(4):371-6. PubMed ID: 6349743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison between the combination emepronium bromide/flavoxate and emepronium bromide in the treatment of detrusor instability.
    Aagaard J; Reuther K; Stimpel H
    Urol Int; 1983; 38(3):191-2. PubMed ID: 6868218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of urgency and urge incontinence with flavoxate in the People's Republic of China.
    Gu FL; Reng ZY; Shang GZ; Shao HX; Wang B; Cheng ZD; Jiang Y; Zhao WP; Zheng JF; Qu CT
    J Int Med Res; 1987; 15(5):312-8. PubMed ID: 3315777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urodynamic response of unstable bladder to flavoxate.
    Zanollo A; Catanzaro F
    Urol Int; 1980; 35(3):176-81. PubMed ID: 7385465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticholinergics for urinary symptoms in multiple sclerosis.
    Nicholas RS; Friede T; Hollis S; Young CA
    Cochrane Database Syst Rev; 2009 Jan; (1):CD004193. PubMed ID: 19160231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detrusor hyperreflexia in female urinary incontinence treated pharmacologically.
    Walter S
    Urol Int; 1978; 33(5):316-21. PubMed ID: 30198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A calcium blocking and anticholinergic agent (terodiline) in the treatment of detrusor hyperreflexia: a placebo-controlled, cross-over trial.
    Petersen T; Jakobsen J
    J Neurol Neurosurg Psychiatry; 1987 Oct; 50(10):1331-6. PubMed ID: 3681312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Urodynamic studies on detrusor hyperreflexia. III. Clinical treatment of detrusor hyperreflexia by TURP, oral administration of flavoxate and prolonged bladder distension (author's transl)].
    Furuya S; Yokoyama E; Kumamoto Y; Tsukamoto T
    Nihon Hinyokika Gakkai Zasshi; 1981 Dec; 72(12):1597-604. PubMed ID: 7345197
    [No Abstract]   [Full Text] [Related]  

  • 11. Double-blind, placebo-controlled, cross-over study of flavoxate in the treatment of idiopathic detrusor instability.
    Chapple CR; Parkhouse H; Gardener C; Milroy EJ
    Br J Urol; 1990 Nov; 66(5):491-4. PubMed ID: 2249117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flavoxate hydrochloride for urinary urgency after pelvic radiotherapy: comparison of 600 mg versus 1200 mg daily dosages.
    Milani R; Scalambrino S; Carrera S; Pezzoli P; Ruffmann R
    J Int Med Res; 1988; 16(1):71-4. PubMed ID: 3350206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Editorial: Hyperactivity of the bladder].
    Hald T
    Ugeskr Laeger; 1973 Oct; 135(43):2333-4. PubMed ID: 4149552
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of flavoxate on hyperactive detrusor muscle.
    Jonas U; Petri E; Kissel J
    Eur Urol; 1979; 5(2):106-9. PubMed ID: 421699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A controlled clinical trial of a new bladder spasmolytic drug--Urispadol].
    Frimodt-Moller C; Hald T; Folkenborg O
    Ugeskr Laeger; 1973 Oct; 135(43):2321-4. PubMed ID: 4149551
    [No Abstract]   [Full Text] [Related]  

  • 16. Placebo--the drug of choice in female motor urge incontinence?
    Meyhoff HH; Gerstenberg TC; Nordling J
    Br J Urol; 1983 Feb; 55(1):34-7. PubMed ID: 6337667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical effects of terodiline hydrochloride on urinary frequency and sense of residual urine--a double blind clinical trial using flavoxate hydrochloride as a control].
    Ogawa A; Shimazaki J; Mitsuya H; Miyazaki S; Kurita T
    Hinyokika Kiyo; 1988 Apr; 34(4):739-53. PubMed ID: 3041785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of flavoxate hydrochloride in daily dosages of 600 versus 1200 mg for the treatment of urgency and urge incontinence.
    Milani R; Scalambrino S; Carrera S; Pezzoli P; Ruffmann R
    J Int Med Res; 1988; 16(3):244-8. PubMed ID: 3044876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Terodiline in the treatment of women with urgency and motor urge incontinence. A clinical and urodynamic double-blind cross-over study.
    Gerstenberg TC; Klarskov P; Ramirez D; Hald T
    Br J Urol; 1986 Apr; 58(2):129-33. PubMed ID: 3516296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bladder cooling reflex in patients with multiple sclerosis.
    Ismael SS; Epstein T; Bayle B; Denys P; Amarenco G
    J Urol; 2000 Oct; 164(4):1280-4. PubMed ID: 10992381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.